MARKET

PHAR

PHAR

Pharming Group N.V.
NASDAQ
16.31
0.00
0.00%
After Hours: 16.31 0 0.00% 16:10 03/27 EDT
OPEN
16.16
PREV CLOSE
16.31
HIGH
16.47
LOW
15.69
VOLUME
26.53K
TURNOVER
--
52 WEEK HIGH
21.34
52 WEEK LOW
7.50
MARKET CAP
1.12B
P/E (TTM)
407.75
1D
5D
1M
3M
1Y
5Y
1D
Pharming granted EU backing for rare immunodeficiency therapy
Seeking Alpha · 22h ago
Pharming Group Wins Positive EMA Panel Backing for Joenja in Rare APDS
TipRanks · 1d ago
EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR HYMPAVZI
Reuters · 1d ago
Pharming Group gains positive EMA CHMP opinion for Joenja in APDS; European Commission decision expected in Q2 FY2026
Reuters · 1d ago
Pharming's Joenja Edges Closer To Becoming First EU-Approved APDS Treatment After Positive CHMP Opinion With European Commission Decision Due Q2 2026
Benzinga · 1d ago
PHARMING GROUP NV - FINAL EUROPEAN COMMISSION DECISION EXPECTED IN Q2 2026
Reuters · 1d ago
Pharming Group Price Target Maintained With a $37.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
Analysts Offer Insights on Healthcare Companies: Pharming Group (PHAR) and Kura Oncology (KURA)
TipRanks · 3d ago
More
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Webull offers Pharming Group NV stock information, including NASDAQ: PHAR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHAR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHAR stock methods without spending real money on the virtual paper trading platform.